EMBL Ventures raises new life sciences fund
This article was originally published in Scrip
Executive Summary
EMBL Ventures, the life sciences-focused venture capital arm of the European Molecular Biology Laboratory, has bucked fundraising trends by completing a first close of its second fund EMBL Technology Fund II at €40 million ($55 million). EMBL Ventures' target is to raise more than €50 million.